The combination of PADCEV and KEYTRUDA has shown a significant improvement in both event-free survival and overall survival for patients with muscle-invasive bladder cancer who are not eligible for cisplatin-based chemotherapy.
Allogene Therapeutics, a clinical-stage biotechnology company, has selected the standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study.
AstraZeneca‘s supplemental biologics license application (sBLA) for Imfinzi (durvalumab) has been approved and given priority review in the U.S. FDAÂ for the treatment of patients with [Read More…]
AstraZeneca announced groundbreaking results from its FLAURA2 Phase III trial, revealing that Tagrisso (osimertinib) combined with chemotherapy offers a statistically significant and clinically meaningful improvement in overall survival for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Pfizer and Astellas report groundbreaking Phase 3 EMBARK trial results showing XTANDI® (enzalutamide) plus leuprolide significantly improves overall survival in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence. This marks the first time an androgen receptor inhibitor-based therapy has shown a definitive survival benefit in this specific patient population, offering new hope for extending lives through early and effective treatment.
Johnson & Johnson subsidiary Janssen-Cilag International NV has applied to the European Medicines Agency (EMA) to increase the usage of AKEEGA®, its cancer medication. To [Read More…]
Amgen has announced positive topline results from the Phase 3 FIGHT trial evaluating bemarituzumab in combination with chemotherapy for advanced gastric and gastroesophageal junction (GEJ) cancer.
AstraZeneca’s Datroway has received US FDA approval for advanced EGFR-mutated lung cancer. This first-in-class TROP2-directed therapy offers a vital new option for patients who have exhausted previous treatments.
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, [Read More…]
Johnson & Johnson reported encouraging new results from a Phase 1b trial that found its experimental oral medicine, bleximenib, given with the routine treatment regimen [Read More…]
